Clinical Trial: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: A Phase II Study of Chlorambucil in Combination With Subcutaneous Rituximab Followed by Maintenance Therapy With Subcutaneous Rituximab in Patients With Extranodal Marginal Zone B-cell Same as current

Current Secondary Outcome:

• Response Rate [ Time Frame: week 25 ]
  Response rate (Complete and partial remission rates) for all patients
• Event-free-survival (EFS) [ Time Frame: at 5 years ]

Original Secondary Outcome: Same as current

Information By: International Extranodal Lymphoma Study Group (IELSG)

Dates:
Date Received: March 6, 2013
Date Started: December 2013
Date Completion: September 2028
Last Updated: July 26, 2016
Last Verified: July 2016